admin – Page 3787 – Get News Story

Tile Adhesive Market Set to Reach USD 51.91 Billion, with a Healthy 13.50% CAGR Till 2032

“Tile Adhesive Market”

Rapidly growing building & construction sector coupled with rising per capita disposable income in developed and developing countries across the globe

The global tile adhesive market has witnessed significant growth over the past decade, driven by increasing construction activities, urbanization, and the rising demand for durable and aesthetically pleasing tiling solutions. Tile adhesives, which are used to bond tiles to various surfaces, have become an essential component in both residential and commercial construction projects. The market is characterized by a diverse range of products, including cementitious, dispersion, and reactive adhesives, each catering to specific application needs.

The tile adhesive market size was valued at USD 21.39 billion in 2023. The tile adhesive industry is projected to grow from USD 23.45 Billion in 2024 to USD 51.91 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.50% during the forecast period (2024 – 2032).

The market’s growth is fueled by the increasing demand for advanced adhesives that offer superior bonding strength, water resistance, and flexibility. Additionally, the rising popularity of large-format tiles and the growing emphasis on sustainable construction practices are contributing to the market’s expansion.

Key Drivers of the Tile Adhesive Market

Rising Construction Activities: The surge in residential, commercial, and infrastructure projects across emerging economies such as China, India, and Brazil is a major driver of the tile adhesive market. Governments in these regions are investing heavily in urban development, which is boosting the demand for construction materials, including tile adhesives.
Urbanization and Population Growth: Rapid urbanization and population growth are leading to increased demand for housing and commercial spaces. This, in turn, is driving the need for high-quality tile adhesives that ensure long-lasting and visually appealing flooring solutions.
Technological Advancements: Innovations in adhesive formulations, such as the development of eco-friendly and low-VOC (volatile organic compound) adhesives, are gaining traction among environmentally conscious consumers. Manufacturers are also focusing on creating adhesives that are easy to apply and offer enhanced performance under various conditions.
Growing Preference for Large-Format Tiles: The trend of using large-format tiles in modern construction projects is boosting the demand for specialized adhesives that can securely bond these tiles to surfaces. Large-format tiles require adhesives with high bonding strength and flexibility to prevent cracking and ensure durability.
Increasing Awareness of Aesthetic Flooring: Consumers are increasingly prioritizing aesthetics in their living and working spaces. Tile adhesives play a crucial role in achieving seamless and visually appealing tile installations, which is driving their adoption in both residential and commercial projects.

Get Free Sample Copy of Report : https://www.marketresearchfuture.com/sample_request/1731

Challenges in the Tile Adhesive Market Despite the positive growth outlook, the tile adhesive market faces several challenges. These include fluctuating raw material prices, stringent environmental regulations, and competition from alternative flooring solutions such as vinyl and laminate. Additionally, the lack of skilled labor for tile installation in some regions can hinder market growth.

Tile Adhesive Market Segmentation

Tile Adhesive Type Outlook

Cementitious
Dispersion
Reactive Tile Adhesive

Tile Adhesive Polymer Chemistry Outlook

Acrylic
Vinyl Acetate Ethylene
Have-Veova
Epoxy
Styrene Butadiene
Polyurethane
Others

Tile Adhesive Application Outlook

Ceramic Tile
Vitrified Tiles
Natural Stone
Mosaic
Glass

Ask for Customization: https://www.marketresearchfuture.com/ask_for_customize/1731

Regional Insights

Asia-Pacific: The Asia-Pacific region dominates the global tile adhesive market, accounting for the largest share in terms of both volume and revenue. The region’s growth is driven by rapid urbanization, infrastructure development, and the presence of key manufacturing hubs in countries like China and India.
North America: The North American market is characterized by the increasing adoption of advanced adhesives and the growing trend of home renovation projects. The demand for eco-friendly and low-VOC adhesives is particularly high in this region.
Europe: Europe is witnessing steady growth in the tile adhesive market, supported by the region’s focus on sustainable construction practices and the renovation of aging infrastructure.
Middle East & Africa: The Middle East and Africa region is expected to experience significant growth due to ongoing infrastructure projects and the rising demand for modern housing solutions.

Browse the Complete Report : https://www.marketresearchfuture.com/reports/tile-adhesive-market-1731

Company News and Developments The tile adhesive market is highly competitive, with several key players striving to strengthen their market position through product innovations, mergers and acquisitions, and strategic partnerships. Below are some recent developments in the industry:

BASF SE: BASF SE, a German chemical company, has been investing in research and development to create innovative tile adhesive solutions. In 2022, the company launched a new range of tile adhesives under its MasterTile brand, which are designed to provide superior adhesion and durability. BASF has also been focusing on developing sustainable products, with a particular emphasis on reducing the carbon footprint of its manufacturing processes. The company has recently entered into a strategic partnership with a leading construction firm to promote the use of eco-friendly tile adhesives in large-scale infrastructure projects.
Sika AG: Sika AG, a Swiss multinational specialty chemicals company, announced the acquisition of a regional tile adhesive manufacturer in Southeast Asia in early 2023. This acquisition is part of Sika’s strategy to expand its footprint in high-growth markets and enhance its product portfolio.
Saint-Gobain Weber: Saint-Gobain Weber, a subsidiary of the French multinational Saint-Gobain, introduced a new line of high-performance tile adhesives designed for large-format tiles in 2023. The products offer exceptional bonding strength and flexibility, catering to the growing demand for modern tiling solutions.
Pidilite Industries Limited: Pidilite, a leading Indian adhesives manufacturer, expanded its tile adhesive product range with the launch of “Fevicol SmartCare,” a premium adhesive designed for high-moisture areas such as bathrooms and kitchens. The product has gained significant traction in the Indian market due to its superior water resistance and ease of application.

Related Reports

Tile Adhesives Stone Adhesive Market

https://www.marketresearchfuture.com/reports/tile-adhesives-stone-adhesive-market-25544

Tile Stone Adhesive Market

https://www.marketresearchfuture.com/reports/tile-stone-adhesive-market-25560

U.S. Tile Adhesive Market

https://www.marketresearchfuture.com/reports/u-s-tile-adhesive-market-4275

Paper Dye Market

https://www.marketresearchfuture.com/reports/paper-dyes-market-3108

Textile Dyes Market

https://www.marketresearchfuture.com/reports/textile-dyes-market-3111

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. The MRFR team have a supreme objective to provide the optimum quality market research and intelligence services for our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,

5Th Floor, New York,

New York 10013

United States of America +1 628 258 0071

Email: sales@marketresearchfuture.com

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tile Adhesive Market Set to Reach USD 51.91 Billion, with a Healthy 13.50% CAGR Till 2032

Clarifying Agents Market Insights: Market Drivers, Restraints, Opportunities, Exploring Current Trends and Growth

“Browse 303 market data Tables and 50 Figures spread through 242 Pages and in-depth TOC on “Clarifying Agents Market””

The Clarifying Agents Market is mainly led by the significant usage of different polymers such as PP, PE, and PET in containers and packaging application in food & beverage industry. The retail sector in emerging countries such as India, Brazil, and China is becoming organized.

The clarifying agents market is projected to reach USD 338 million by 2027, at a CAGR of 7.5% from USD 235 million in 2022. The market growth is driven by influencing factors such as significant demand from end-industries such as packaging, consumer products, and electronics. This report provides a comprehensive analysis of industry, including clarifying agents market size, trends, drivers and constraints, competitive aspects, and prospects for future growth.

The clarifying agents market is mainly driven by the demand for different types of polymers such as PP, PE, and PET in packaging applications, increase in consumption of plastics, growing usage in pharmaceutical applcations. Moreover, it is also driven by rapidly developing and emerging economies such as India, Brazil, and Argentina.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=15165588

“Granules form is projected to grow at fastest CAGR, in terms of volume, during the forecast period”

Granules form is projected to be the fastest growing segment in global clarifying agents market, in terms of valuee, during the forecast period. Considering its cost-effectiveness, granule form clarifying agents are finding its relevant use in packaging and consumer products application in various industries. Granule form is made compatible with conventional feeders and can achieve decent efficiency in material handling.

“PET is projected to be the fastest growing polymer in clarifying agents market, in terms of value”

Polyethylene terephthalate (PET) is considered as a semi-crystalline polymer with lightweight and colourlessness. Ethylene glycol and dimethyl terephthalate are used in the production of PET. It is widely used for packages drinking water and airated soft drinks across the globe. The organized retail industry is boosting the market for packed food and beverages and thereby driving the clarifying agents market.

“Asia Pacific is expected to be the fastest growing market for clarifying agents during the forecast period, in terms of value and volume.”

The significant growth of the packaging industry coupled with the increasing demand for packaged food & beverages are projected to lead the growth of clarifying agents market in this region. China is estimated to be the largest market for clarifying agents in the region.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=15165588

The presence of key companies, such as ADEKA Corporation (Japan), New Japan Chemical Co., Ltd. (Japan), and GCH Technology Co., Ltd. (China), and established polymer manufacturing facilities in this region are projected to drive the demand for clarifying agents.

Clarifying Agents Companies

The key global players in the clarifying agents market include Milliken & Company (US), ADEKA Corporation (Japan), Shandong Rainwell New Materials Technology Co., Ltd. (China), Avient Corporation (US), BASF SE (Germany), New Japan Chemical Co., Ltd. (Japan), GCH Technology Co., Ltd. (China), Qingdao Jade New Material Technology (China), Guangzhou Bolong Chemical Co. Ltd. (China), and Ta Haw Enterprise Co. Ltd. (Taiwan). These companies are strong in their home regions and explore geographic diversification alternatives to grow their businesses. They focus on increasing their market shares through new product launches, and other expansions.

Milliken & Company

Milliken & Company is the leading manufacturer of clarifying agents. The company offers clarifying agents through the chemical business segment and serves several markets, including automotive & transportation, building & construction, coatings, paints & inks, comfort, consumer goods, electronics, medical, and packaging. The company has registered more than 5,500 patents since 1927. It has a strong geographical presence with more than 70 global locations, 44 plants, 18 offices/labs, ten showrooms, and six distribution centers. In March 2019, Milliken increased the production capacity for clarifiers by 50% in the US. This expansion is expected to meet the increase in demand and reduce the carbon footprint during the manufacture of PP products. In October 2019, Milliken launched Millad NX 8000 ECO, a clarifying agent for polypropylene (PP) tailored for use in the extrusion blow molding (EBM) process.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=15165588

ADEKA Corporation

ADEKA Corporation is one of the leading manufacturers of clarifying agents. Its operations are carried out through the following segments: chemical, life sciences, food products, and others. The chemical products segment produces semiconductor materials, electronic circuit board etching equipment, light-curing resin, optical recording materials, polymer additives, polyvinyl chloride stabilizers, plasticizers, flame retardants, epoxy resin, surfactants, lubricating oil additives, propylene glycol, and hydrogen peroxide. The company offers clarifying agents through its polymer additives segment under the chemical segment. It has a presence in Europe, Asia Pacific, North America, and South America.

Shandong Rainwell New Materials Technology Co., Ltd.

Shandong Rainwell New Materials Technology Co., Ltd. is a high-tech enterprise integrating both research & development and production. The company is involved in the manufacturing and R&D of light stabilizers, antioxidants, fluoropolymer processing aids, and various compounded granulating additives. The company is equipped to serve its customers with products and services, as well as a complete set of customized solutions for the chemical and plastic industries. Shandong Rainwell New Materials Technology Co., Ltd. has clarifying agent production bases with the largest production capacity.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/clarifying-agents-market-15165588.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clarifying Agents Market Insights: Market Drivers, Restraints, Opportunities, Exploring Current Trends and Growth

Postoperative Pain Management Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Lab

The Key Postoperative Pain Management Companies in the market include – Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others.

DelveInsight’s “Postoperative Pain Management Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postoperative Pain Management, historical and forecasted epidemiology as well as the Postoperative Pain Management market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postoperative Pain Management market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Pain Management Market Forecast

Some of the key facts of the Postoperative Pain Management Market Report:

The Postoperative Pain Management market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In February 2025, Allay Therapeutics administered the first dose in its randomized Phase IIb registration trial evaluating ATX101, an investigational analgesic aimed at delivering prolonged pain relief after total knee replacement surgery.
In January 2024, Heron Therapeutics announced that the FDA approved its supplemental New Drug Application (sNDA) for bupivacaine and meloxicam extended-release solution. The approval expands its indication to include soft tissue and orthopedic surgical procedures, specifically those where direct exposure to articular cartilage is avoided.
Key Postoperative Pain Management Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Postoperative Pain Management Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
The Postoperative Pain Management market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Pain Management pipeline products will significantly revolutionize the Postoperative Pain Management market dynamics.

Postoperative Pain Management Overview

Postoperative pain management refers to the strategies and treatments used to alleviate pain following surgery. Effective pain control enhances patient recovery, reduces complications, and improves overall comfort. Management approaches include opioid and non-opioid analgesics, regional anesthesia (nerve blocks, epidurals), non-pharmacological methods (cold therapy, physiotherapy), and multimodal pain management to minimize side effects and optimize relief. Personalized treatment plans are crucial to balance pain control with minimizing the risk of opioid dependence and other complications.

Get a Free sample for the Postoperative Pain Management Market Report:

https://www.delveinsight.com/report-store/post-operative-pain-management-market

Postoperative Pain Management Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postoperative Pain Management Epidemiology Segmentation:

The Postoperative Pain Management market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Number of Incident Cases of Postoperative Pain Management in the 7MM
Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM
Severity-specific Incident Cases of Postoperative Pain Management in the 7MM

Download the report to understand which factors are driving Postoperative Pain Management epidemiology trends @ Postoperative Pain Management Epidemiology Forecast

Postoperative Pain Management Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain Management market or expected to get launched during the study period. The analysis covers Postoperative Pain Management market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postoperative Pain Management Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postoperative Pain Management Therapies and Key Companies

DEXTENZA (dexamethasone): Ocular Therapeutix
ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
IV Tramadol: Avenue Therapeutics
TLC590: Taiwan Liposome Company (TLC)
TPU-006: Teikoku Pharma USA
CA-008: Concentric Analgesics
SVT-15473: Salvat Laboratories
VX-548: Vertex Pharmaceuticals
OCS-01: Oculis
N1539: Baudax Bio
SHR0410: Jiangsu HengRui Medicine
Ketorolac tromethamine: Darnitsa Pharma
AYX1: Adynxx, Inc.
EXPAREL: Pacira Pharma
Toragesic®: Apsen Farmaceutica S.A.
SABER-Bupivacaine: Durect
lyrica: Pfizer
VVZ-149: Vivozon, Inc.
Tapentadol (OS): Grünenthal GmbH
Percocet: Mallinckrodt
YM177: Astellas Pharma Inc
LMX4: Ferndale Laboratories, Inc.

Discover more about therapies set to grab major Postoperative Pain Management market share @ Postoperative Pain Management Treatment Market

Postoperative Pain Management Market Strengths

Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.
Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Postoperative Pain Management Market Opportunities

Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.
Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat Postoperative Pain Management.

Scope of the Postoperative Pain Management Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Postoperative Pain Management Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Postoperative Pain Management Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
Postoperative Pain Management Therapeutic Assessment: Postoperative Pain Management current marketed and Postoperative Pain Management emerging therapies
Postoperative Pain Management Market Dynamics: Postoperative Pain Management market drivers and Postoperative Pain Management market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Postoperative Pain Management Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Management Market Access and Reimbursement

To know more about Postoperative Pain Management companies working in the treatment market, visit @ Postoperative Pain Management Clinical Trials and Therapeutic Assessment

Table of Contents

1. Postoperative Pain Management Market Report Introduction

2. Executive Summary for Postoperative Pain Management

3. SWOT analysis of Postoperative Pain Management

4. Postoperative Pain Management Patient Share (%) Overview at a Glance

5. Postoperative Pain Management Market Overview at a Glance

6. Postoperative Pain Management Disease Background and Overview

7. Postoperative Pain Management Epidemiology and Patient Population

8. Country-Specific Patient Population of Postoperative Pain Management

9. Postoperative Pain Management Current Treatment and Medical Practices

10. Postoperative Pain Management Unmet Needs

11. Postoperative Pain Management Emerging Therapies

12. Postoperative Pain Management Market Outlook

13. Country-Wise Postoperative Pain Management Market Analysis (2019–2032)

14. Postoperative Pain Management Market Access and Reimbursement of Therapies

15. Postoperative Pain Management Market Drivers

16. Postoperative Pain Management Market Barriers

17. Postoperative Pain Management Appendix

18. Postoperative Pain Management Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postoperative Pain Management Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Lab

George Yuhasz’s Righteous Allegiance Tackles the Dangerous Rise of Extremism in America in a High-Stakes Thriller about Politics, Race and Justice

In Righteous Allegiance, George Yuhasz crafts a powerful and timely thriller that mirrors America’s current struggles with division, extremism, and racial tension. Filled with danger, political intrigue, and heart-pounding twists, the book recently became a #1 Amazon Bestseller.

Set in a divided America, Righteous Allegiance immerses readers in the shadowy world of government espionage and domestic terror. Will Manley, a rising star in the U.S. clandestine services, is tasked with infiltrating a radical group bent on reshaping the nation through violence and white supremacy. At the center of this dangerous plot is Elias McArdle, a ruthless former U.S. Army commander intent on destabilizing the government to create a new world order rooted in hate. As McArdle manipulates powerful forces, FBI agent Ron Shortridge works tirelessly to unravel a complex web of deception before an imminent act of terror transforms the nation.

But this is not just a story of action and intrigue. Through Rebecca Hurney, a wise Lenape elder, and the symbolic presence of a mysterious red fox, Righteous Allegiance offers readers a deeply original exploration of healing, heritage, and the enduring wisdom of Native American culture. These elements elevate the story beyond a traditional thriller, providing a unique and compelling perspective rarely seen in the genre.

Adding to its authenticity, George Yuhasz’s extensive background as a former U.S. Government special agent, intelligence officer, and contractor lends unparalleled realism to the narrative. Drawing from his firsthand experience, Yuhasz offers an authentic perspective of the challenges, complexities, and moral ambiguities inherent in intelligence work.

“I wanted Righteous Allegiance to be more than just a thriller,” says Yuhasz. “This is a story about the choices we make when the stakes are at their highest—about reconciling who we are with what we believe in and standing up against darkness. By weaving together elements of political intrigue, Native American culture, and personal sacrifice, I hope to encourage readers to consider the power of kindness, resilience, and courage in a divided world.”

Righteous Allegiance has garnered glowing reviews from critics and readers alike. IndieReader calls it, “a vibrant narrative with highly drawn characters, captivating readers in a story that combines personal sacrifice with a nation’s struggle for freedom.” In addition, Book Excellence praises it as “a pulse-pounding story with a powerful message…not to be missed.”

With echoes of Vince Flynn’s Mitch Rapp, Lee Child’s Jack Reacher, and Tom Clancy’s Jack Ryan, Righteous Allegiance stands out as a must-read for fans of suspenseful, action-packed fiction. The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, and other online bookstores. Readers are encouraged to get their copy today: https://www.amazon.com/Righteous-Allegiance-George-Yuhasz-ebook/dp/B0DKCPZYYK

About the Author

George Yuhasz is a 13X award-winning author and a former U.S. Government special agent, intelligence officer, and contractor. He has also worked in the private sector as an investigator and security consultant.

George is the author of the pulse-pounding thriller, RIGHTEOUS ALLEGIANCE, and the heartwarming, uplifting children’s book, IMAGINE THAT: THE MAGIC OF THE MYSTERIOUS LIGHTS. His writing has been honored with numerous international literary awards, including two from the Independent Author Network, two from the Firebird Book Awards, an IndieB.R.A.G. Medallion, and awards from the Book Excellence Awards, Eric Hoffer Book Awards, Wishing Shelf Book Awards, Royal Dragonfly Book Awards, Independent Press Book Awards, and the American Writing Awards.

George earned a B.A. degree with a double major in international service and government from American University and holds a M.A. degree in psychology from the University of Northern Colorado. He is a member of the Association of Former Intelligence Officers and is a Certified Protection Professional Life Member of the American Society for Industrial Security.

George lives in the Blue Ridge Mountains of Western North Carolina.

To connect with George and learn more about his work, visit: www.georgeyuhaszauthor.com. You can also find him on Linkedin, Facebook (@GeorgeYuhaszAuthor), X (@GeorgeYuhasz), and Bluesky (@georgeyuhasz-7.bsky.social)

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: George Yuhasz’s Righteous Allegiance Tackles the Dangerous Rise of Extremism in America in a High-Stakes Thriller about Politics, Race and Justice

Tonic clonic Seizure Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharma, UCB Pharma, Johnson & Johnson, Ono Pharma

The Key Tonic clonic Seizure Companiesin theamrket include – Emory University, Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharmaceuticals, UCB Pharma, Johnson & Johnson, Ono Pharmaceutical, Zogenix, Inc., and others.

DelveInsight’s “Tonic clonic Seizure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tonic clonic Seizure, historical and forecasted epidemiology as well as the Tonic clonic Seizure market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Tonic clonic Seizure, offering comprehensive insights into the Tonic clonic Seizure revenue trends, prevalence, and treatment landscape. The report delves into key Tonic clonic Seizure statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Tonic clonic Seizure therapies. Additionally, we cover the landscape of Tonic clonic Seizure clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Tonic clonic Seizure treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Tonic clonic Seizure space.

To Know in detail about the Tonic clonic Seizure market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tonic clonic Seizure Market Forecast

Some of the key facts of the Tonic clonic Seizure Market Report:

The Tonic clonic Seizure market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In June 2024, UCB, a leading global biopharmaceutical company, announced that Epilepsia has published findings from a comprehensive scoping review assessing the effectiveness of FINTEPLA® (fenfluramine) in reducing generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The analysis demonstrated a notable decrease in both GTCS and TCS across different DEEs, further reinforcing the existing clinical data from the FINTEPLA trial program.
Generalized tonic-clonic seizures affect approximately 0.5–1% of the global population, often linked to epilepsy.
Can occur at any age but is more common in childhood and adolescence, with a second peak in older adults.
Affects both males and females equally, though some studies suggest a slightly higher prevalence in males.
Individuals with a family history of epilepsy have a higher likelihood of developing tonic-clonic seizures.
Often associated with neurological disorders, including stroke, traumatic brain injuries, and neurodegenerative diseases.
Key Tonic clonic Seizure Companies: Emory University, Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharmaceuticals, UCB Pharma, Johnson & Johnson, Ono Pharmaceutical, Zogenix, Inc., and others
Key Tonic clonic Seizure Therapies: Keppra, Pregabalin, lamotrigine (LAMICTAL), Perampanel, XEN1101, Levetiracetam, topiramate, Cenobamate, ZX008, and others
The Tonic clonic Seizure market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tonic clonic Seizure pipeline products will significantly revolutionize the Tonic clonic Seizure market dynamics.

Tonic clonic Seizure Overview

Tonic-Clonic Seizure (formerly known as a grand mal seizure) is a type of generalized seizure that affects the entire brain. It consists of two phases: Tonic Phase – The body stiffens, muscles contract, and the person may lose consciousness. Clonic Phase – Rapid, rhythmic jerking movements occur in the arms and legs. These seizures typically last 1–3 minutes and may be followed by confusion, fatigue, or headache. Medical attention is required if a seizure lasts longer than 5 minutes.

Get a Free sample for the Tonic clonic Seizure Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/tonic-clonic-seizure-market

Tonic clonic Seizure Epidemiology

Tonic clonic Seizure Epidemiology Segmentation:

The Tonic clonic Seizure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Tonic clonic Seizure
Prevalent Cases of Tonic clonic Seizure by severity
Gender-specific Prevalence of Tonic clonic Seizure
Diagnosed Cases of Episodic and Chronic Tonic clonic Seizure

Download the report to understand which factors are driving Tonic clonic Seizure epidemiology trends @ Tonic clonic Seizure Epidemiology Forecast

Tonic clonic Seizure Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tonic clonic Seizure market or expected to get launched during the study period. The analysis covers Tonic clonic Seizure market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Tonic clonic Seizure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tonic clonic Seizure Therapies and Key Companies

Keppra: Emory University
Pregabalin: Pfizer
lamotrigine (LAMICTAL): GlaxoSmithKline
Perampanel: Eisai Inc.
XEN1101: Xenon Pharmaceuticals
Levetiracetam: UCB Pharma
topiramate: Johnson & Johnson
Cenobamate: Ono Pharmaceutical
ZX008: Zogenix, Inc.

Discover more about therapies set to grab major Tonic clonic Seizure market share @ Tonic clonic Seizure Treatment Landscape

Tonic clonic Seizure Market Drivers

Rising Prevalence of Epilepsy
Advancements in Antiepileptic Drugs (AEDs)
Growing Awareness and Diagnosis Rates
Government Support and Funding
Expanding Use of Wearable Seizure Monitoring Devices
Increasing Research in Gene Therapy and Neurostimulation

Tonic clonic Seizure Market Barriers

High Treatment Costs
Side Effects of Medications
Limited Availability of Neurologists and Epilepsy Specialists
Social Stigma and Psychological Impact
Challenges in Drug Development
Risk of Sudden Unexpected Death in Epilepsy (SUDEP)

Scope of the Tonic clonic Seizure Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Tonic clonic Seizure Companies: Emory University, Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharmaceuticals, UCB Pharma, Johnson & Johnson, Ono Pharmaceutical, Zogenix, Inc., and others
Key Tonic clonic Seizure Therapies: Keppra, Pregabalin, lamotrigine (LAMICTAL), Perampanel, XEN1101, Levetiracetam, topiramate, Cenobamate, ZX008, and others
Tonic clonic Seizure Therapeutic Assessment: Tonic clonic Seizure current marketed and Tonic clonic Seizure emerging therapies
Tonic clonic Seizure Market Dynamics: Tonic clonic Seizure market drivers and Tonic clonic Seizure market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Tonic clonic Seizure Unmet Needs, KOL’s views, Analyst’s views, Tonic clonic Seizure Market Access and Reimbursement

To know more about Tonic clonic Seizure companies working in the treatment market, visit @ Tonic clonic Seizure Clinical Trials and Therapeutic Assessment

Table of Contents

1. Tonic clonic Seizure Market Report Introduction

2. Executive Summary for Tonic clonic Seizure

3. SWOT analysis of Tonic clonic Seizure

4. Tonic clonic Seizure Patient Share (%) Overview at a Glance

5. Tonic clonic Seizure Market Overview at a Glance

6. Tonic clonic Seizure Disease Background and Overview

7. Tonic clonic Seizure Epidemiology and Patient Population

8. Country-Specific Patient Population of Tonic clonic Seizure

9. Tonic clonic Seizure Current Treatment and Medical Practices

10. Tonic clonic Seizure Unmet Needs

11. Tonic clonic Seizure Emerging Therapies

12. Tonic clonic Seizure Market Outlook

13. Country-Wise Tonic clonic Seizure Market Analysis (2019–2032)

14. Tonic clonic Seizure Market Access and Reimbursement of Therapies

15. Tonic clonic Seizure Market Drivers

16. Tonic clonic Seizure Market Barriers

17. Tonic clonic Seizure Appendix

18. Tonic clonic Seizure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tonic clonic Seizure Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharma, UCB Pharma, Johnson & Johnson, Ono Pharma

New Homes in Richmond VA | Miller and Smith Expands Thoughtful Community Living

“Miller and Smith’s Vision for New Homes Richmond VA. Miller and Smith stand apart by committing to intentional neighborhood design that includes bringing thoughtfully planned communal spaces to their new homes in Richmond Va. Cutting-edge, sustainable, and technological innovations. A boutique home-buying experience. This approach ensures lasting value and satisfaction for homeowners and investors alike.”

Miller and Smith expands into Richmond, VA, recognizing its growing housing market driven by job growth, affordability, and migration trends. The company’s intentional and innovative approach delivers sustainable, modern homes and vibrant community living, catering to homebuyers and investors seeking lasting value and quality.

Richmond, VA – Miller and Smith, a premier boutique homebuilder known for thoughtful, community-centric residential developments, proudly announces its strategic expansion into Richmond, Virginia. Recognizing Richmond’s robust economic growth, affordability, and increasing demand for modern, intentional home designs, Miller and Smith is committed to shaping vibrant communities that reflect the evolving needs of residents and investors alike.

New Homes Forsale in Richmond Va - Thoughtful Home Design Richmond

Richmond: A Market Primed for Growth

Richmond’s real estate market has surged due to key economic drivers, including a thriving job market, affordability compared to Northern Virginia, and significant population migration. Major companies such as Capital One, Altria, and an expanding technology sector continue to attract professionals, making Richmond a leading choice for families, young professionals, and retirees seeking high-quality living without the high costs. Read more About it in our research based, deep dive articles on LinkedIn. Be sure to subscribe to stay up to date with the latest research as we continue to share all of our findings.

Why New Construction in Richmond is Trending

Homebuyers in Richmond increasingly favor new construction over resale homes, driven by the desire for energy-efficient features, contemporary designs, and low maintenance living. Miller and Smith meet these demands by incorporating advanced sustainability practices, smart home technology, and thoughtfully planned layouts with open-concept spaces and flexible living areas. Their communities are designed to enhance quality of life with extensive amenities, green spaces, and walkability.

Expanding to Richmond – Why It's the Perfect Market for Intentional Design

Miller and Smith: Elevating Community Standards

Miller and Smith’s approach is distinguished by its boutique-style commitment to personalized experiences and intentional design. Unlike mass-production builders, the company’s developments prioritize sustainability, technological integration, and communal connectivity. Every community crafted by Miller and Smith reflects a dedication to both quality and enduring value, positioning homeowners and investors for lasting appreciation.

Investment Opportunities in Richmond

Richmond presents a compelling investment landscape marked by rising home values, a robust rental market supported by Virginia Commonwealth University and a strong professional workforce, and ongoing economic expansion. Miller and Smith’s proven track record and reputation for excellence provide investors a solid foundation for sustained returns.

Join Richmond’s Exciting New Chapter

Miller and Smith invite homebuyers and investors to explore their innovative Richmond communities, where intentional design meets community-driven living.

For more information or to schedule a community tour, visit Miller & Smith Richmond Communities.

Media Contact
Company Name: Miller and Smith
Contact Person: Sara Buehl
Email: Send Email
Phone: 703-975-2982
City: Vienna
State: VA
Country: United States
Website: https://millerandsmith.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Homes in Richmond VA | Miller and Smith Expands Thoughtful Community Living

Panic Disorder Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Pfizer, Honeybrains Biotech, Cerevel Therapeutics, Samsung Medical Center

The Key Panic Disorder Companies in the market include – Pfizer, Honeybrains Biotech LLC, Cerevel Therapeutics, Massachusetts General Hospital, Samsung Medical Center, Indiana University, UCB Pharma, and others.

DelveInsight’s “Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Panic Disorder, offering comprehensive insights into the Panic Disorder revenue trends, prevalence, and treatment landscape. The report delves into key Panic Disorder statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Panic Disorder therapies. Additionally, we cover the landscape of Panic Disorder clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Panic Disorder treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Panic Disorder space.

To Know in detail about the Panic Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Panic Disorder Market Forecast

Some of the key facts of the Panic Disorder Market Report:

The Panic Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Panic disorder affects approximately 2–3% of the global population annually.
Typically begins in late adolescence to early adulthood, with most cases emerging between ages 20 and 40.
Women are twice as likely as men to develop panic disorder.
Often coexists with generalized anxiety disorder (GAD), depression, and substance use disorders.
Individuals with a family history of anxiety disorders have a higher risk of developing panic disorder.
Key Panic Disorder Companies: Pfizer, Honeybrains Biotech LLC, Cerevel Therapeutics, Massachusetts General Hospital, Samsung Medical Center, Indiana University, UCB Pharma, and others
Key Panic Disorder Therapies: VENLAFAXINE, HB-01, Darigabat, Duloxetine, Lexapro, quetiapine XR, Niravam, and others
The Panic Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Panic Disorder pipeline products will significantly revolutionize the Panic Disorder market dynamics.

Panic Disorder Overview

Panic Disorder is an anxiety disorder characterized by recurrent and unexpected panic attacks, which are sudden episodes of intense fear accompanied by physical symptoms such as rapid heartbeat, sweating, shortness of breath, dizziness, and chest pain. These attacks often occur without a clear trigger and can lead to persistent worry about future episodes, causing individuals to avoid certain situations. Panic disorder can significantly impact daily life but is manageable with therapy, medication, and lifestyle changes.

Get a Free sample for the Panic Disorder Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/panic-disorder-market

Panic Disorder Epidemiology

Panic Disorder Epidemiology Segmentation:

The Panic Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Panic Disorder
Prevalent Cases of Panic Disorder by severity
Gender-specific Prevalence of Panic Disorder
Diagnosed Cases of Episodic and Chronic Panic Disorder

Download the report to understand which factors are driving Panic Disorder epidemiology trends @ Panic Disorder Epidemiology Forecast

Panic Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Panic Disorder market or expected to get launched during the study period. The analysis covers Panic Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Panic Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Panic Disorder Therapies and Key Companies

VENLAFAXINE: Pfizer
HB-01: Honeybrains Biotech LLC
Darigabat: Cerevel Therapeutics
Duloxetine: Massachusetts General Hospital
Lexapro: Samsung Medical Center
quetiapine XR: Indiana University
Niravam: UCB Pharma

Discover more about therapies set to grab major Panic Disorder market share @ Panic Disorder Treatment Landscape

Panic Disorder Market Drivers

Rising Prevalence of Anxiety Disorders
Growing Awareness and Diagnosis Rates
Advancements in Treatment Options
Increased Government Initiatives
Expanding Telemedicine and Digital Health Solutions

Panic Disorder Market Barriers

Social Stigma and Misconceptions
High Cost of Treatment
Side Effects of Medications
Limited Availability of Mental Health Professionals
Delayed Diagnosis and Underreporting

Scope of the Panic Disorder Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Panic Disorder Companies: Pfizer, Honeybrains Biotech LLC, Cerevel Therapeutics, Massachusetts General Hospital, Samsung Medical Center, Indiana University, UCB Pharma, and others
Key Panic Disorder Therapies: VENLAFAXINE, HB-01, Darigabat, Duloxetine, Lexapro, quetiapine XR, Niravam, and others
Panic Disorder Therapeutic Assessment: Panic Disorder current marketed and Panic Disorder emerging therapies
Panic Disorder Market Dynamics: Panic Disorder market drivers and Panic Disorder market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Panic Disorder Unmet Needs, KOL’s views, Analyst’s views, Panic Disorder Market Access and Reimbursement

To know more about Panic Disorder companies working in the treatment market, visit @ Panic Disorder Clinical Trials and Therapeutic Assessment

Table of Contents

1. Panic Disorder Market Report Introduction

2. Executive Summary for Panic Disorder

3. SWOT analysis of Panic Disorder

4. Panic Disorder Patient Share (%) Overview at a Glance

5. Panic Disorder Market Overview at a Glance

6. Panic Disorder Disease Background and Overview

7. Panic Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Panic Disorder

9. Panic Disorder Current Treatment and Medical Practices

10. Panic Disorder Unmet Needs

11. Panic Disorder Emerging Therapies

12. Panic Disorder Market Outlook

13. Country-Wise Panic Disorder Market Analysis (2019–2032)

14. Panic Disorder Market Access and Reimbursement of Therapies

15. Panic Disorder Market Drivers

16. Panic Disorder Market Barriers

17. Panic Disorder Appendix

18. Panic Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Panic Disorder Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Pfizer, Honeybrains Biotech, Cerevel Therapeutics, Samsung Medical Center

Myelofibrosis Market is Expected to Flourish in 7MM, Expanding from USD 1.7 Billion in 2024 | DelveInsight

The Myelofibrosis companies involved in the development pipeline includes – BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb and Merck), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), RVU120 (Ryvu Therapeutics), TP-3654 (Sumitomo Pharma), SNT-5505 (Syntara), DISC-0974 (Disc Medicine), and ELZONRIS (Menarini Group), among others.

The myelofibrosis treatment market is going to witness robust growth owing to the launch of emerging therapies by key players such as Abbvie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, Ns Pharma, Galecto Biotech, Actuate Therapeutics, Merck, Menarini Group, Telios Pharma, Disc Medicine, Syntara, Sumitomo Pharma, and Incyte, among others, which are advancing myelofibrosis research to address unmet needs.

DelveInsight’s “Myelofibrosis Market Insight, Epidemiology And Market Forecast – 2034” report provides an in-depth understanding of Myelofibrosis, historical and forecasted epidemiology, as well as the Myelofibrosis market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The myelofibrosis market size, valued at ~USD 1.7 billion in 2024, is projected to expand at a rapid CAGR over the forecasted period (2025–2034). This growth is fueled by rising disease prevalence, improved diagnostic capabilities, and the launch of novel therapies targeting diverse patient subgroups. Among all the therapies, JAKAFI/JAKAVI (ruxolitinib) accounted for the largest myelofibrosis market size in 2024, with USD 1.5 Billion.

Download the myelofibrosis market report to understand which factors are driving the myelofibrosis market @ myelofibrosis Market Trends

The report provides a comprehensive epidemiological analysis and forecasts extending to 2034. This analysis is segmented by total myelofibrosis prevalent cases, type-specific cases, myelofibrosis cases based on risk stratification, age-specific myelofibrosis cases, and myelofibrosis cases based on molecular alterations in the 7MM.

According to DelveInsight’s analysis, the total myelofibrosis prevalence in the 7MM was nearly 56K in 2024. High-risk myelofibrosis accounted for the largest patient population in the US, with primary myelofibrosis making up approximately 75% of all cases. This trend is expected to continue in the forecasted period (2025–2034).

For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival. Key marketed therapies include JAKAFI (ruxolitinib) and INREBIC (fedratinib), which have dominated the landscape as JAK inhibitors provide unprecedented benefits to myelofibrosis patients in terms of spleen shrinkage and symptom improvement. However, the patent for JAKAFI is expected to go off in 2027 for Novartis and in 2028 for Incyte, opening up opportunities for emerging therapies.

As JAK inhibitor therapy is linked with certain complications, new treatments for myelofibrosis are focusing on mechanisms other than JAK inhibitors. These include imetelstat (telomerase inhibitor), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), and others that may meet the patient’s needs and provide an alternative myelofibrosis treatment.

According to DelveInsight’s analysis, the myelofibrosis competitive landscape is further enriched by several companies initiating clinical trials for new options. The pipeline includes drugs such as BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb and Merck), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), RVU120 (Ryvu Therapeutics), TP-3654 (Sumitomo Pharma), SNT-5505 (Syntara), DISC-0974 (Disc Medicine), and ELZONRIS (Menarini Group), among others.

Discover evolving trends in myelofibrosis treatment landscape @ myelofibrosis therapies

Other than JAKAFI and INREBIC, the current myelofibrosis treatment landscape also includes approved drugs like VONJO (CTI BioPharma), a JAK2/IRAK1 inhibitor, approved back in 2022 for the treatment of adults with the intermediate or high-risk primary or secondary myelofibrosis. OJJAARA (GSK), a JAK1/2 and ACVR1 inhibitor targeting anemia, which is the only approved agent for both newly diagnosed and previously treated patients with myelofibrosis and anemia, was approved in 2023. Omjjara’s unique mechanism addressing hepcidin dysregulation positions it to reshape the secondary myelofibrosis treatment market, particularly for anemic patients who face limited options.

Unlock which myelofibrosis emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Myelofibrosis Market Insights

The myelofibrosis treatment clinical trial pipeline is currently active, with notable recent breakthroughs. In January 2025, the BOREAS phase 3 trial demonstrated that navtemadlin, an MDM2 inhibitor, offers clinical benefits as a single agent in JAK inhibitor–refractory myelofibrosis, showing durable spleen volume reductions and symptom improvements. In March 2025, a Phase 3 trial showed that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone in treating myelofibrosis, with significant spleen shrinkage and no substantial increase in side effects. These recent findings indicate a strong upward trend in the myelofibrosis treatment market.

Despite these advancements, challenges persist. Long-term JAK inhibitor use is linked to cytopenias and infections, while high treatment costs and accessibility barriers limit global reach. DelveInsight’s analysis emphasizes the need for cost-effective therapies and personalized approaches leveraging genetic profiling.

Looking ahead, the myelofibrosis treatment market is poised for diversification with a robust developmental pipeline, including BET inhibitors, PI3K inhibitors, and immunomodulators. The integration of biomarkers and combination regimens is expected to enhance response durability and address resistance.

Table of Contents

1.	KEY INSIGHTS
2.	REPORT INTRODUCTION
3.	EXECUTIVE SUMMARY OF MYELOFIBROSIS
4.	EPIDEMIOLOGY AND MARKET METHODOLOGY
5.	KEY EVENTS
6.	MYELOFIBROSIS MARKET OVERVIEW AT A GLANCE
7.	DISEASE BACKGROUND AND OVERVIEW
8.	TREATMENT AND MANAGEMENT
9.	GUIDELINES
10.	EPIDEMIOLOGY AND PATIENT POPULATION
11.	PATIENT JOURNEY
12.	KEY ENDPOINTS IN MYELOFIBROSIS CLINICAL TRIALS
13.	MARKETED DRUGS
14.	EMERGING THERAPIES
15.	MYELOFIBROSIS: 7 MAJOR MARKET ANALYSIS
16.	MARKET ACCESS AND REIMBURSEMENT
17.	SWOT ANALYSIS
18.	UNMET NEEDS
19.	KOL VIEWS
20.	APPENDIX
21.	DELVEINSIGHT CAPABILITIES
22.	DISCLAIMER
23.	ABOUT DELVEINSIGHT

Related Report

Myelofibrosis Pipeline Insight

Myelofibrosis Pipeline Insight provides comprehensive insights about the Myelofibrosis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Myelofibrosis companies, including Geron Corporation, Merck, Telios Pharma, Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, and Sumitomo Pharma America, Inc. among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Market is Expected to Flourish in 7MM, Expanding from USD 1.7 Billion in 2024 | DelveInsight

Chronic Pain Market Growth Projections 2024-2034: DelveInsight Analysis | Pacira BioSciences, Paradigm Biopharma, Tonix Pharma

The Key Chronic Pain Companies in the market include – Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others.

DelveInsight’s “Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast

Some of the key facts of the Chronic Pain Market Report:

The Chronic Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In February 2025, BioRestorative Therapies announced that the FDA cleared its Investigational New Drug (IND) application for BRTX-100, a novel cell-based therapeutic for treating chronic cervical discogenic pain (cCDP) by targeting areas with little blood flow.
In January 2025, Zynex Inc. expanded its portfolio of non-invasive medical devices for pain management and rehabilitation. The FDA recently cleared Zynex’s TensWave device, which uses Transcutaneous Electrical Nerve Stimulation (TENS) therapy for portable, drug-free pain relief. Zynex’s flagship NexWave device, clinically proven to reduce chronic pain, combines multiple therapeutic modalities for effective pain management.
In 2023, the United States recorded the highest prevalence of chronic pain cases among the total 7MM regions.
Among the EU4 and the UK, the United Kingdom had the highest prevalence of chronic pain cases, accounting for approximately 30%.
The prevalence of chronic pain increased with age, with the highest rates observed in individuals aged 45 to 64 years.
In 2023, around 70% of chronic pain cases in the United States were classified as moderate to severe in terms of severity.
Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium),TNX-102 SL, and others
The Chronic Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain pipeline products will significantly revolutionize the Chronic Pain market dynamics.

Chronic Pain Overview

Chronic Pain is a type of nerve damage caused by prolonged high blood sugar levels in individuals with diabetes. It typically affects the feet and legs, leading to symptoms like burning, tingling, sharp pain, or numbness. This condition occurs when high blood sugar damages the nerves, resulting in abnormal pain signals. The pain can be persistent and difficult to manage, affecting daily activities. Treatment often includes pain relievers, anticonvulsants, antidepressants, and lifestyle changes to help control blood sugar levels and manage symptoms.

Get a Free sample for the Chronic Pain Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-pain-market

Chronic Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Pain Epidemiology Segmentation:

The Chronic Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Chronic Pain
Prevalent Cases of Chronic Pain by severity
Gender-specific Prevalence of Chronic Pain
Diagnosed Cases of Episodic and Chronic Chronic Pain

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast

Chronic Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain market or expected to get launched during the study period. The analysis covers Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Chronic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Pain Therapies and Key Companies

JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
TNX-102 SL: Tonix Pharmaceuticals

Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Landscape

Scope of the Chronic Pain Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium),TNX-102 SL, and others
Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement

To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Pain Market Report Introduction

2. Executive Summary for Chronic Pain

3. SWOT analysis of Chronic Pain

4. Chronic Pain Patient Share (%) Overview at a Glance

5. Chronic Pain Market Overview at a Glance

6. Chronic Pain Disease Background and Overview

7. Chronic Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Pain

9. Chronic Pain Current Treatment and Medical Practices

10. Chronic Pain Unmet Needs

11. Chronic Pain Emerging Therapies

12. Chronic Pain Market Outlook

13. Country-Wise Chronic Pain Market Analysis (2020–2034)

14. Chronic Pain Market Access and Reimbursement of Therapies

15. Chronic Pain Market Drivers

16. Chronic Pain Market Barriers

17. Chronic Pain Appendix

18. Chronic Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Pain Market Growth Projections 2024-2034: DelveInsight Analysis | Pacira BioSciences, Paradigm Biopharma, Tonix Pharma

O’Connor Company Welcomes Jon Spicher as Project Executive

Industry veteran brings extensive experience in large-scale project execution and leadership development

Pinehurst – Mar 19, 2025 – O’Connor Company, a leading name in commercial construction specializing in delivering high-quality projects across diverse sectors, is proud to announce the addition of Jon Spicher as Project Executive, bringing with him a proven track record in managing large-scale construction projects and developing high-performing teams. His leadership will enhance the company’s ability to execute complex projects efficiently, strengthen workforce development, and support its long-term growth strategy.

In his new role, Jon will oversee all aspects of project execution, ensuring that quality, efficiency, and client satisfaction remain at the forefront. He will lead and mentor the company’s Project Managers and Assistant Project Managers, reinforcing a culture of collaboration, accountability, and continuous improvement. His expertise will play a crucial role in streamlining project operations and supporting O’Connor Company’s expansion into larger and more complex developments.

“Jon’s ability to optimize project execution while developing future leaders within our team makes him a perfect fit for O’Connor Company,” said Clark Lowe, President & CEO. “His leadership will help us scale as we take on more ambitious projects while maintaining the level of excellence our clients expect.”

Jon’s background includes leading multi-million-dollar projects such as the $72M Port of Albany Expansion, as well as overseeing major heavy civil, commercial, and municipal infrastructure developments. His ability to manage budgets, schedules, and stakeholder coordination will bring immediate value to O’Connor Company’s growing project portfolio.

“With Jon’s expertise, we are further strengthening our ability to execute complex projects at scale,” said Zach Froio, Vice President of Preconstruction. “His experience and leadership will allow us to refine our processes, expand our market presence, and take on new challenges with confidence.”

Jon’s addition to the leadership team directly supports O’Connor Company’s long-term growth strategy by enhancing project oversight, refining workforce development initiatives, and ensuring scalability as the company takes on increasingly complex projects. His leadership will be instrumental in optimizing operational efficiency, mentoring project managers, and driving a performance-driven culture across the organization.

Jon will immediately step into overseeing key projects while implementing strategies to enhance team performance and operational efficiency. His leadership will help position O’Connor Company for sustained success while reinforcing its commitment to delivering top-tier results in commercial construction.

For more information about O’Connor Company and its ongoing projects, please visit https://www.buildoconnor.com.

About O’Connor Company

O’Connor Company is a leading name in commercial construction, specializing in delivering high-quality projects across diverse sectors. With a reputation for innovation, efficiency, and client satisfaction, O’Connor Company leverages cutting-edge practices to redefine the construction industry. From healthcare to retail and now community-focused initiatives, the company remains at the forefront of delivering projects that make a lasting impact

Media Contact
Company Name: Otter PR
Contact Person: Mark Hashem
Email: Send Email
Phone: 7274339069
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: O’Connor Company Welcomes Jon Spicher as Project Executive